Becker's Healthcare January 6, 2025
Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.
RAS gene mutations are found in 20% of all cancers and are associated with lower survival rates compared to those without RAS gene mutations, according to a Dec. 6 news release from the institute.
The new center will be led by Alice Shaw, MD, PhD, thoracic medical oncologist and chief of strategic partnerships at Dana-Farber, and Andrew Aguirre, MD, PhD, gastrointestinal medical oncologist and physician-scientist at both Dana-Farber and Cambridge, Mass.-based Broad Institute of Harvard and MIT.
The center will accelerate drug development to improve outcomes as well as...
Today's Sponsors
Today's Sponsor